tetano
Editor, Senior Moderator
Clin Infect Dis
. 2022 Apr 22;ciac226.
doi: 10.1093/cid/ciac226. Online ahead of print.
Reduced Cell Surface Levels of C-C Chemokine Receptor 5 and Immunosuppression in Long Coronavirus Disease 2019 Syndrome
Norman B Gaylis[SUP] 1 [/SUP], Angela Ritter[SUP] 2 [/SUP], Scott A Kelly[SUP] 3 [/SUP], Nader Z Pourhassan[SUP] 3 [/SUP], Meenakshi Tiwary[SUP] 4 [/SUP], Jonah B Sacha[SUP] 4 [/SUP], Scott G Hansen[SUP] 4 [/SUP], Christopher Recknor[SUP] 3 [/SUP], Otto O Yang[SUP] 5 6 [/SUP]
Affiliations
Abstract
In an exploratory trial treating "long COVID" with the CCR5-binding antibody leronlimab, we observed significantly increased blood cell surface CCR5 in treated symptomatic responders but not in nonresponders or placebo-treated participants. These findings suggest an unexpected mechanism of abnormal immune downmodulation in some persons that is normalized by leronlimab. Clinical Trials Registration. NCT04678830.
Keywords: CCR5; immunosuppression; leronlimab; long COVID.
. 2022 Apr 22;ciac226.
doi: 10.1093/cid/ciac226. Online ahead of print.
Reduced Cell Surface Levels of C-C Chemokine Receptor 5 and Immunosuppression in Long Coronavirus Disease 2019 Syndrome
Norman B Gaylis[SUP] 1 [/SUP], Angela Ritter[SUP] 2 [/SUP], Scott A Kelly[SUP] 3 [/SUP], Nader Z Pourhassan[SUP] 3 [/SUP], Meenakshi Tiwary[SUP] 4 [/SUP], Jonah B Sacha[SUP] 4 [/SUP], Scott G Hansen[SUP] 4 [/SUP], Christopher Recknor[SUP] 3 [/SUP], Otto O Yang[SUP] 5 6 [/SUP]
Affiliations
- PMID: 35452519
- DOI: 10.1093/cid/ciac226
Abstract
In an exploratory trial treating "long COVID" with the CCR5-binding antibody leronlimab, we observed significantly increased blood cell surface CCR5 in treated symptomatic responders but not in nonresponders or placebo-treated participants. These findings suggest an unexpected mechanism of abnormal immune downmodulation in some persons that is normalized by leronlimab. Clinical Trials Registration. NCT04678830.
Keywords: CCR5; immunosuppression; leronlimab; long COVID.